Which manufacturer produces the original drug capmatinib (Touradida) and its production qualifications

Capmatinib (capmatinib) is an oral small molecule MET inhibitor, mainly used to treat MET exon 14 skipping mutation-positive non-small cell lung cancer (NSCLC) patients. The original drug was jointly developed by Incyte Incyte and Novartis in the United States, and Novartis is responsible for global marketing and production management. As the world's leading pharmaceutical company, Novartis has rich experience and strict management systems in drug research and development, production and quality control, ensuring the high quality and stability of the original drug capmatinib.

In terms of production qualifications, the production plants of the original drug Capmatinib have obtained GMP certification from the US FDA and EMA, which means that its production process complies with international drug production quality management standards and ensures the safety and consistency of the drug in production, packaging and storage. GMP Certification is an important prerequisite for drugs to enter the international market. It is also an important guarantee for ensuring drug efficacy and patient safety.

In addition, the original drug capmatinib adopts advanced technology in the production process, including high-precision chemical synthesis, purification and quality testing methods. Each batch of drugs must undergo strict quality testing before leaving the factory, including content uniformity, dissolution, impurity control, microbial limits and other indicators to ensure the stability and safety of the drug ingredients. This strict quality management system provides reliable guarantee for clinical application.

Generally speaking, the original drug capmatinib is produced by an internationally renowned pharmaceutical company and has a complete GMP certification and quality management system. When patients use the original drug, they can achieve higher drug safety and stable efficacy. At the same time, doctors can also refer to the production qualification information of drugs when prescribing, provide patients with scientific and standardized medication suggestions, and ensure the safety and reliability of the treatment process.

Reference link:https://www.drugs.com